Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy

Takuma Narita(Nagoya City University), Shinsuke Iida(Nagoya City University)

Blood Cancer Journal

December 4, 2015

10.1038/bcj.2015.98

Cited by 49

Related Papers

Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing

|Blood Cancer Journal|2012|181

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma

|PLoS ONE|2018|28